MoonLake Immunotherapeutics (MLTX) company profile
Close on Nov 17, 2026Market cap $957.45MP/E –Yield –
About MoonLake Immunotherapeutics
Pharmaceutical Preparations, SIC 2834
MoonLake Immunotherapeutics is a clinical-stage biotechnology company that develops therapies for inflammatory skin and joint disorders. The firm operates as a single-asset entity centered on the clinical evaluation of SLK, an investigational tri-specific Nanobody that inhibits interleukin-17A and interleukin-17F. Its research and development activities target inflammatory conditions within dermatology and rheumatology, primarily hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, and axial spondyloarthritis. Because its therapeutic candidate remains in clinical development, the company has no commercial sales, and its intended end users are patients suffering from these inflammatory conditions.
The provided text does not identify the company's headquarters. In terms of operational scale and geography, the company conducts global clinical trial programs that encompass several international multi-center studies, as well as trial sites within the United States. Its clinical activities involve engagements with regulatory authorities, including the United States Food and Drug Administration and the European Medicines Agency. The company also utilizes external contract manufacturing organizations for drug substance and drug product manufacturing.
Summary of the business section of MoonLake Immunotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MoonLake Immunotherapeutics
- Headquarters
- Zug, V8
- Address
- Dorfstrasse 29 6300
- Phone
- 41 41 510 8022
- Website
- moonlaketx.com
- Employees
- 130, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Santa Clara, California
Stock & identifiers
- Ticker
- MLTX
- Former tickers
- HLXA until Apr 11, 2022
- Exchange
- Nasdaq
- IPO date
- Oct 21, 2020
- Shares outstanding
- 85M, Aug 1, 2026
- Public float
- $1.34B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1821586
- CUSIP
- 61559X104
- ISIN
- US61559X1046
- FIGI
- BBG00XQZQTS9
- Share class FIGI
- BBG00XQZQVP7
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| da Silva Jorge Santos | Chief Executive Officer, Director | 2,774,893 |
| Kristian Reich | Chief Scientific Officer | 2,746,587 |
| Matthias Bodenstedt | Chief Financial Officer | 1,115,435 |
| I. Gp Llc Bvf | Director | 10,235,089 |
| Value Fund Ii Lp Biotechnology | Director | 11,265,678 |
| Mark N. Lampert | Director | 1,039,238 |
| Value Trading Fund OS LP Biotechnology | Director | – |
| Partners L. P/Il Bvf | Director | – |
| Value Fund L. P. Biotechnology | Director | – |
| Partners OS Ltd. BVF | Director | 6,599,722 |
| Ii Gp Llc Bvf | Director | – |
| Inc/Il Bvf | Director | 1,287,768 |
| Gp Holdings Llc Bvf | Director | 9,005,700 |
| Andrew John Phillips | Director | – |
| Catherine Moukheibir | Director | 23,500 |
| Ramnik Xavier | Director | – |
| Spike Loy | Director | – |
| Simon Sturge | Director | 171,980 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.94M | $340.96K | $4.74M | $133 | $109 |
| FY2024 | $1.41M | -$225.07K | $1.17M | $548 | $81 |
| FY2023 | $1.20M | $17.02M | $1.06M | $611 | $80 |
| FY2022 | $4.48M | $2.13M | $5.10M | $106 | $74 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Dr. Jorge Santos da Silva Chief Executive Officer and Interim Chair of the Board | $762.39K | $4.00M | – | $180.80K | $4.94M | +252% |
| Matthias Bodenstedt Chief Financial Officer | $603.56K | $4.00M | – | $89.00K | $4.69M | +354% |
| Dr. Kristian Reich Chief Scientific Officer | $762.39K | – | $4.00M | $33.09K | $4.80M | +268% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Oct 21, 2020
- Offer price
- $10.00
- Exchange
- Nasdaq
- First trading day
- Oct 20, 2020
- First-day close
- $10.49+4.9%
- Lock-up ends (est.)
- Apr 18, 2021
“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have grown to a team of approximately 130 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 17, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 16, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 11, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 31, 2022 | Name change | Name changed from Helix Acquisition Corp to MoonLake Immunotherapeutics |
| Feb 14, 2022 | Merger vote | Definitive merger proxy statement |
| May 18, 2021 | Late filing | Notification of late filing |
| Oct 21, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 19, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?